Home / Health / FDA OKs Labcorp Test for Melanoma Therapy
FDA OKs Labcorp Test for Melanoma Therapy
10 Aug
Summary
- Labcorp's companion diagnostic for advanced melanoma received FDA approval.
- The test identifies patients with specific BRAF mutations for targeted treatment.
- The oncology diagnostics market is projected to exceed $3.1bn by 2030.
The U.S. Food and Drug Administration (FDA) has granted approval for Labcorp's companion diagnostic, PGDx elio tissue complete CDx. This in vitro diagnostic test utilizes next-generation sequencing to identify advanced melanoma patients who possess specific BRAF mutations, namely V600E and V600K. Identifying these mutations is crucial as they indicate suitability for targeted therapies, including BRAF inhibitors and combination regimens.
Melanoma, the deadliest form of skin cancer, has a particularly low survival rate for stage IV disease. The prevalence of BRAF mutations in approximately 50% of melanomas, with V600E being the most common, makes this diagnostic tool invaluable. Labcorp's CDx aims to improve patient access to timely and effective treatments by enabling clinicians to quickly confirm eligibility for targeted therapies.
This approval underscores the growing significance of companion diagnostics in precision oncology. Projections indicate that the global oncology diagnostics market will surpass $3.1 billion by 2030, highlighting the expanding role of CDx in matching patients with optimal therapeutic strategies for improved outcomes.
